Business EconomyPosted at: May 16 2026 9:42PM


Dr. Reddy’s launches generic Semaglutide injection in Canada

Hyderabad, May 16 (UNI) Dr. Reddy’s Laboratories, the Hyderabad-based global pharmaceutical major, on Saturday announced the launch of its generic Semaglutide Injection in Canada.
Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market following the Notice of Compliance (NOC) granted by Health Canada on April 28, 2026.
Canada has become the first G7 nation to grant market authorisation for generic Semaglutide Injection, marking a significant milestone in the global expansion of GLP-1 therapies, the pharmaceutical company said in a release here.
According to the company, the launch reflects Dr. Reddy’s preparedness to ensure rapid patient access following regulatory approval.
In Canada, Dr. Reddy’s Semaglutide Injection is indicated as a once-weekly treatment for adults with Type 2 Diabetes Mellitus to improve glycaemic control alongside diet and exercise.
The medication is supplied as a sterile solution for subcutaneous injection in pre-filled pens and is available in 2 mg/pen and 4 mg/pen strengths. Each pen delivers semaglutide at a concentration of 1.34 mg/ml.
The 2 mg pen is designed to administer 0.25 mg or 0.5 mg doses, while the 4 mg pen delivers 1 mg per injection.
Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We are pleased to launch our generic Semaglutide Injection in Canada within days of receiving Health Canada approval. This milestone highlights our readiness to serve Canadian patients, supported by our deep expertise in complex drug and peptide development.”
“With our well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality and affordable GLP-1 therapies closer to patients,” he added.
The Canada launch follows the company’s recent introduction of the drug in India under the brand name Obeda®.
“As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets,” Erez Israeli said.
Semaglutide Injection is intended for adult patients with Type 2 diabetes to improve glycaemic control in combination with diet and exercise, particularly where metformin is unsuitable due to contraindications or intolerance.
The company clarified that Semaglutide has not been studied in combination with short-acting prandial insulin and should not be considered a substitute for insulin.
It is also not indicated for patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.
UNI KNR RN
Please log in to get detailed story.
Tags: #Dr. Reddy’s launches generic Semaglutide injection in Canada
More News

Hyd: Dr Reddy's CFO Narasimham Named 'Best CFO in Pharmaceuticals

10 Jun 2026 | 11:33 PM

Hyderabad, June 10 (UNI) Dr. Reddy's Laboratories Ltd. on Wednesday announced that its Chief Financial Officer, M.V. Narasimham, has been honoured with the 'Best CFO in Pharmaceuticals' award at the 9th BW CFO World's Best CFO & Finance Strategy Excellence Awards 2026 organised by Businessworld.

see more..

ECLGS 5 0 guarantees cross 1 lakh mark, covers over Rs 48,000 Cr in credit protection

10 Jun 2026 | 7:09 PM

New Delhi, June 10 (UNI) The Emergency Credit Line Guarantee Scheme (ECLGS) 5.0 has crossed a significant milestone, with the total number of guarantees issued under the scheme surpassing the 1 lakh mark as of June 9, 2026.

see more..

Telangana's Singareni gets Rs 40 cr refund for successful closure of Dorli-2 Opencast Mine

10 Jun 2026 | 6:35 PM

Hyderabad, June 10 (UNI) The Singareni Collieries Company Limited (SCCL) has received approval for the refund of nearly Rs 40 crore, including accrued interest, from the Coal Controller Organisation (CCO) following the successful closure of the Dorli-2 Opencast Mine in Bellampalli Area in accordance with the Ministry of Coal's guidelines.

see more..

Deccan Gold signs Spain tungsten deal, targets 51% stake

10 Jun 2026 | 6:35 PM

Bengaluru, June 10 (UNI) Deccan Gold Mines Ltd has announced the signing of a definitive Earn-In, Option and Shareholders Agreement for the Logrosan Tungsten Project in Spain, marking a strategic expansion into critical minerals amid rising global demand for secure resource supply chains.

see more..

Govt extends CGSMFI-2 0, enhances loan limit for large NBFC-MFIs

10 Jun 2026 | 5:56 PM

New Delhi, June 10 (UNI): The government has approved an extension in the validity of the Credit Guarantee Scheme for Microfinance Institutions-2.0 (CGSMFI-2.0) up to August (31.8.2026) or till guarantees for an amount of Rs 20,000 crore are issued, whichever is earlier, the Finance Ministry statement said here on Wednesday.

see more..